As healthcare institutions are looking to adopt new technologies to better assist patients, telehealth is becoming a prominent resource for many practitioners. By providing the ability to call or video conference with healthcare providers, institutions can offer patients the care they need from the comfort of their own homes.
Based on the results of the oncology nurse navigator (ONN) role delineation survey and feedback from ONS membership, ONS evaluated and updated its ONN Core Competencies. Several significant changes were made.
Disparities continue to create a wide gap in health in the United States. Many factors can contribute to a person’s health, and we still have much to learn about the issue. The U.S. Food and Drug Administration (FDA) has announced it will be dedicating research funding to find out more about how lifestyle impacts health.
Prescription drug abuse has reached epic proportions in the United States. Efforts have been made to help combat this growing issue. In 2016, President Obama signed into law the Comprehensive Addiction and Recovery Act (CARA) to reclassify drug abuse as a disease instead of a crime.
On May 18, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to pembrolizumab (Keytruda®, Merck and Co., Inc.) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Melanomas that resemble seborrheic keratosis (SK) can be challenging to diagnose correctly. SKs are often removed without being evaluated dermascopically or sent for pathologic analysis, risking the possibility of missing a diagnosis of SK-like melanoma. A new study published in JAMA Dermatology outlined the key dermascopic clues that clinicians can use to identify SK-like melanomas to prevent treatment delays and achieve the best patient outcomes.
The latest edition of the Annual Report to the Nation on the Status of Cancer, 1975-2014, confirms that death rates are decreasing for 11 of the 16 most common types of cancer in men and 13 of the 18 most common types in women.
As more new treatments enter practice—like immunotherapy, targeted therapy, and combination therapies—oncology nurses are required to be experts in every treatment they administer. They need to constantly walk a tightrope, balancing multiple medications for one patient then quickly moving to the next patient on a completely different treatment protocol.
Two members of the House of Representatives have put political party differences aside and introduced bipartisan legislation that requires health insurers to cover traditional chemotherapy, along with oral medications associated with cancer treatment. U.S. Representatives Leonard Lance (R-NJ) and Brian Higgins (D-NY) have proposed the Cancer Drug Parity Act (H.R. 1409). The intent of the bill is to ensure appropriate oncologic treatments are affordable and covered for patients with cancer.
One of the key factors to a cancer clinical trial’s success is the ability to enroll an adequate number of patients in an appropriate timeframe. Identifying barriers to slow accrual and ways to address them can help researchers and nurse scientists make big steps in the fight against cancer in the era of the National Cancer Moonshot Initiative.